Sclerostin Antibody Treatment Improves Implant Fixation in a Model of Severe Osteoporosis

• DOI: 10.2106/jbjs.n.00654
• Publication Date: 2015-01-21T19:19:42Z
• Authors: Amarjit S. Virdi; John Irish; Kotaro Sena; Min Liu; Hua Zhu Ke; Margaret A. McNulty; Dale R. Sumner
• Keywords: Sclerostin

Background: The mechanical fixation of orthopaedic and dental implants is compromised by diminished bone volume, such as with osteoporosis. Systemic administration sclerostin antibody (Scl-Ab) has been shown to enhance implant in normal animals. In the present study, we tested whether Scl-Ab can improve established osteoporosis a rat model. Methods: We used an ovariectomized (ovx) model, which found 78% decrease trabecular volume at time surgery; sham-ovx, age-matched rats were controls. After placement titanium medullary cavity distal aspect femur, maintained for four, eight, or twelve weeks treated biweekly delivery vehicle alone. Outcomes measured use microcomputed tomography, testing, static dynamic histomorphometry. Results: treatment doubled strength both sham-ovx ovx groups, although enhancement was delayed group. also enhanced bone-implant contact; increased peri-implant thickness volume; cortical thickness. These structural changes associated approximately five sevenfold increase bone-formation rate >50% depression eroded surface following treatment. Trabecular contact accounted two-thirds variance strength. Conclusions: this model severe osteoporosis, stimulating formation suppressing resorption, leading improved architecture. Clinical Relevance: anti-sclerostin antibodies might be useful strategy total joint replacement when mass deficient.